A multicenter study in the UK found that maternal vaccination against respiratory syncytial virus (RSV) significantly reduced infant hospitalizations by 72%. Conducted with 537 mother-infant pairs across 30 hospitals, the study revealed the highest efficacy when the vaccine was administered over 14 days before delivery. The bivalent prefusion F vaccine demonstrated an overall effectiveness of 58%, with premature infants and male infants being part of the study group. Notably, no deaths were reported during hospitalization, indicating the need for timely vaccination.

Source: The Lancet Child and Adolescent Health